Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Vanguard Total World Stock Index Fund ETF — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Vanguard Total World Stock Index Fund ETF trades at $157.15 (market cap $101.70B). The key difference: Vanguard Total World Stock Index Fund ETF is far larger — about 11.5× Kymera Therapeutics Inc. Common Stock's market cap, and Kymera Therapeutics Inc. Common Stock is more actively traded (779,107 versus 7,186,242). Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Vanguard Total World Stock Index Fund ETF for 54 Days on average.
| KYMR | VT | |
|---|---|---|
Market Cap | $8.87B | $101.70B |
Volume | 779,107 | 7,186,242 |
Sector | Health | Broad Market / Factor |
52-Week High | $127.31 | $162.39 |
52-Week Low | $55.80 | $134.19 |
Typical Hold Time | 0 Days | 54 Days |
Enterprise Value | $8.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Vanguard Total World Stock ETF (VT) trades at $159.76, showing modest daily gains of 0.16% with neutral technical indicators. The ETF maintains broad global diversification across 9,773 stocks with a low 0.06% expense ratio. Recent news highlights VT's strong five-year performance compared to international-focused peers, though some competitors offer lower fees. Technical analysis shows the ETF trading near pivot point resistance at $160 with support at $159.
VT provides comprehensive global equity exposure but faces fee competition from alternatives like SPDW. The ETF's broad diversification minimizes country-specific risks while capturing global growth. Key risks include expense ratio pressure and emerging market volatility. Analyst sentiment remains positive for long-term investors seeking one-stop global diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
